Nurix Therapeutics 与罗氏达成合作,将共同推进药物Bexobrutinib在慢性淋巴细胞白血病(CLL)、B细胞恶性肿瘤、多发性硬化症(MS)以及慢性自发性荨麻疹(CSU)等多个适应症中的研发进程。
Nurix Therapeutics 与罗氏达成合作,将共同推进药物Bexobrutinib在慢性淋巴细胞白血病(CLL)、B细胞恶性肿瘤、多发性硬化症(MS)以及慢性自发性荨麻疹(CSU)等多个适应症中的研发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.